Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

Autor: Shuiying Hu, Giuliano Ciarimboli, Lie Li, Jhm Schellens, Alix F. Leblanc, Alice A. Gibson, Eberhard Schlatter, Jiyoung Kim, D B Finkelstein, Alex Sparreboom, Aksana Vasilyeva, Kristen W. Hong, Navjotsingh Pabla, Douglas H. Sweet, Sharyn D. Baker, Jason A. Sprowl, Laura J. Janke

Publikováno v: Clinical and Translational Science. 10:412-420

Cisplatin is among the most widely used anticancer drugs and known to cause a dose-limiting nephrotoxicity, which is partially dependent on the renal uptake carrier OCT2. We here report a previously unrecognized, OCT2-independent pathway of cisplatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4faaae966e07fb22ba925343c4a3eb5e
https://doi.org/10.1111/cts.12480

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.

Autor: Knikman JE; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zhai Q; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Henricks LM; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands., Böhringer S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., van der Lee M; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Offer SM; Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA., Shrestha S; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands., Dezentjé VO; Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands., Jeurissen FJF; Department of Internal Medicine, Haaglanden Medical Center, The Hague, The Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Jansen RLH; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands., Droogendijk HJ; Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Nieboer P; Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, The Netherlands., van de Poel MHW; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Mandigers CMPW; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Schellens JHM; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Cats A; Department of Gastroenterology and Hepatology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. h.j.guchelaar@lumc.nl., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Publikováno v: Genome medicine [Genome Med] 2024 Aug 15; Vol. 16 (1), pp. 101. Date of Electronic Publication: 2024 Aug 15.

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.

Autor: Le Teuff G; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France. Gwenael.LETEUFF@gustaveroussy.fr., Cozic N; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Boyer JC; Service de Biochimie et Biologie Moléculaire, CHU Carémeau, Nîmes, France., Boige V; Department of cancer medicine, Gustave-Roussy Cancer Campus, Paris-Saclay and Paris-Sud Universities, Villejuif, France.; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France., Diasio RB; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Cancer Center, Rochester, MN, USA., Taieb J; Université Paris-Cité, SIRIC CARPEM, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP-HP, Paris, France., Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Palles C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Schwab M; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University of Tuebingen, Tuebingen, Germany.; Cluster of Excellence IFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, 72074, Tübingen, Germany., Deenen M; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Largiadèr CR; Department of Clinical Chemistry, Bern University Hospital, University of Bern, Inselspital, Bern, Switzerland., Marinaki A; Purine Research Laboratory, St Thomas' Hospital, London, UK., Jennings BA; Norwich Medical School, University of East Anglia, Norwich, UK., Wettergren Y; Sahlgrenska University Hospital, Goteborg, Sweden., Di Paolo A; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Gross E; LMU Munich, University Hospital, Campus Grosshadern, Munich, Germany., Budai B; National Institute of Oncology, Budapest, Hungary., Ackland SP; College of Heath, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia., van Kuilenburg ABP; Amsterdam UMC, location University of Amsterdam, Laboratory Genetic Metabolic Diseases, Meibergdreef 9, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Imaging and biomarkers, Amsterdam, The Netherlands., McLeod HL; Intermountain Precision Genomics, Intermountain Healthcare, St George, UT, USA., Milano G; Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France., Thomas F; Institut Claudius Regaud, IUCT-Oncopôle and CRCT, University of Toulouse, Inserm, Toulouse, France., Loriot MA; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France.; Hôpital Européen Georges Pompidou, Hôpitaux Universitaires Paris Ouest, Paris, France., Kerr D; Nuffield Division of Clinical and Laboratory Sciences and University of Oxford, Oxford, UK., Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Laurent-Puig P; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC, 5096, Paris, France.; Hôpital Européen Georges Pompidou, Hôpitaux Universitaires Paris Ouest, Paris, France., Shi Q; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Pignon JP; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France., Etienne-Grimaldi MC; Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.

Publikováno v: British journal of cancer [Br J Cancer] 2024 Mar; Vol. 130 (5), pp. 808-818. Date of Electronic Publication: 2024 Jan 15.

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

Autor: Knikman JE; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wilting TA; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Henricks LM; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Late Development Oncology, AstraZeneca, Cambridge, UK., Nieboer P; Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, the Netherlands., Droogendijk HJ; Department of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Mandigers CMPW; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands., Valkenburg-van Iersel L; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands., Vulink A; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., van der Poel MHW; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, the Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Schellens JHM; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Cats A; Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 10; Vol. 41 (35), pp. 5411-5421. Date of Electronic Publication: 2023 Aug 28.

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".

Autor: de With M; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.; Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands., Knikman J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Cats A; Division of Medical Oncology, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Late Development Oncology, AstraZeneca, Cambridge, UK.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Mar; Vol. 113 (3), pp. 473-475. Date of Electronic Publication: 2022 Nov 09.